LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 6 of 15: Mean cell count and mean growth rate across biological replicate 3. - Dataset (ID:20242)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | GSK1059615 | 10.0 | uM | LJP5 | 72 | hr | 1401 | 861 | 4223 | 0.2039 | -0.1916 |
| SK-BR-3 | GSK1059615 | 10.0 | uM | LJP6 | 72 | hr | 1401 | 694 | 4223 | 0.1643 | -0.2508 |
| SK-BR-3 | GSK1904529A | 10.0 | uM | LJP6 | 72 | hr | 1401 | 4299 | 4223 | 1.0181 | 1.0271 |
| SK-BR-3 | Omipalisib | 10.0 | uM | LJP6 | 72 | hr | 1401 | 855 | 4223 | 0.2025 | -0.1937 |
| SK-BR-3 | GSK 690693 | 10.0 | uM | LJP5 | 72 | hr | 1401 | 3008 | 4223 | 0.7123 | 0.5694 |
| SK-BR-3 | GW843682X | 10.0 | uM | LJP6 | 72 | hr | 1401 | 1734 | 4223 | 0.4106 | 0.1178 |
| SK-BR-3 | HG-5-113-01 | 10.0 | uM | LJP5 | 72 | hr | 1401 | 1269 | 4223 | 0.3007 | -0.0467 |
| SK-BR-3 | HG-5-88-01 | 10.0 | uM | LJP6 | 72 | hr | 1401 | 2100 | 4223 | 0.4973 | 0.2476 |
| SK-BR-3 | Imatinib | 10.0 | uM | LJP6 | 72 | hr | 1401 | 4258 | 4223 | 1.0083 | 1.0124 |
| SK-BR-3 | JNK-9L | 10.0 | uM | LJP6 | 72 | hr | 1401 | 1193 | 4223 | 0.2826 | -0.0738 |
| SK-BR-3 | JW-7-24-1 | 10.0 | uM | LJP6 | 72 | hr | 1401 | 1209 | 4223 | 0.2864 | -0.0680 |
| SK-BR-3 | Lapatinib | 10.0 | uM | LJP6 | 72 | hr | 1401 | 1796 | 4223 | 0.4254 | 0.1400 |
| SK-BR-3 | LDN-193189 | 10.0 | uM | LJP5 | 72 | hr | 1401 | 557 | 4223 | 0.1319 | -0.2993 |
| SK-BR-3 | Linifanib | 10.0 | uM | LJP6 | 72 | hr | 1401 | 2159 | 4223 | 0.5112 | 0.2685 |
| SK-BR-3 | Linsitinib | 10.0 | uM | LJP5 | 72 | hr | 1401 | 3075 | 4223 | 0.7281 | 0.5931 |
| SK-BR-3 | Mitoxantrone | 10.0 | uM | LJP5 | 72 | hr | 1401 | 91 | 4223 | 0.0217 | -0.4642 |
| SK-BR-3 | Mitoxantrone | 10.0 | uM | LJP6 | 72 | hr | 1401 | 109 | 4223 | 0.0258 | -0.4581 |
| SK-BR-3 | MK2206 | 10.0 | uM | LJP6 | 72 | hr | 1401 | 1297 | 4223 | 0.3073 | -0.0368 |
| SK-BR-3 | Neratinib | 10.0 | uM | LJP5 | 72 | hr | 1401 | 1344 | 4223 | 0.3184 | -0.0202 |
| SK-BR-3 | Nilotinib | 10.0 | uM | LJP5 | 72 | hr | 1401 | 2065 | 4223 | 0.4890 | 0.2351 |
| SK-BR-3 | Nintedanib | 10.0 | uM | LJP6 | 72 | hr | 1401 | 1350 | 4223 | 0.3198 | -0.0181 |
| SK-BR-3 | NU7441 | 10.0 | uM | LJP5 | 72 | hr | 1401 | 1805 | 4223 | 0.4275 | 0.1431 |
| SK-BR-3 | Dactolisib | 10.0 | uM | LJP5 | 72 | hr | 1401 | 1687 | 4223 | 0.3996 | 0.1014 |
| SK-BR-3 | NVP-TAE684 | 10.0 | uM | LJP6 | 72 | hr | 1401 | 870 | 4223 | 0.2061 | -0.1883 |
| SK-BR-3 | Palbociclib | 10.0 | uM | LJP6 | 72 | hr | 1401 | 2791 | 4223 | 0.6609 | 0.4925 |